Logo

Decode Q2 Loss Up 38 Percent on Revenue Decline, Higher R&D Costs

Aug 09, 2006
NEW YORK (GenomeWeb News) – Decode Genetics said today that second-quarter losses widened 38 percent on falling revenue and soaring research and development costs.
 
Receipts for the three months ended June 30 dropped 9 percent to $10.4 million from $11.4 million in the same quarter last year.
 
The company spent about $13.2 million on R&D in the second quarter, up 20 percent from $11 million in the comparable period last year. The increased costs are associated with Decode’s lead drug-discovery and -development programs, the firm said in a statement.
 
Decode said net loss for the second quarter increased to $18 million from $13 million in Q2 2005. The company attributed the loss to higher R&D costs.
 
As of June 30, Decode had approximately $115.5 million in cash and short-term investments.

Breaking News
The Scan

Genome Sequences Reveal Range Mutations in Induced Pluripotent Stem Cells

Researchers in Nature Genetics detect somatic mutation variation across iPSCs generated from blood or skin fibroblast cell sources, along with selection for BCOR gene mutations.

Researchers Reprogram Plant Roots With Synthetic Genetic Circuit Strategy

Root gene expression was altered with the help of genetic circuits built around a series of synthetic transcriptional regulators in the Nicotiana benthamiana plant in a Science paper.

Infectious Disease Tracking Study Compares Genome Sequencing Approaches

Researchers in BMC Genomics see advantages for capture-based Illumina sequencing and amplicon-based sequencing on the Nanopore instrument, depending on the situation or samples available.

LINE-1 Linked to Premature Aging Conditions

Researchers report in Science Translational Medicine that the accumulation of LINE-1 RNA contributes to premature aging conditions and that symptoms can be improved by targeting them.